Theravance Biopharma (TBPH) Tops Q3 EPS by 4c

Theravance Biopharma (NASDAQ: TBPH) reported Q3 EPS of ($1.40), $0.04 better than the analyst estimate of ($1.44). Revenue for the quarter came in at $10.7 million versus the consensus estimate of $4.24 million.

For earnings history and earnings-related data on Theravance Biopharma (TBPH) click here.

You May Also Be Interested In

• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• Morgan Stanley Downgrades Sims Metal Management Ltd. (SGM:AU) (SMUPF) to Underweight
• JPMorgan Upgrades Whitehaven Coal Ltd. (WHC:AU) (WHITF) to Overweight